Recent Mantle Cell Non-Hodgkin's Lymphoma News

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. ... Continue Reading

Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma (August 9, 2017)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would... Continue Reading

Imbruvica Approved for Mantle Cell Lymphoma (January 23, 2014)

The U.S. Food and Drug Administration (FDA) has approved Imbruvica™ (ibrutinib) for the treatment of patients with mantle cell lymphoma, a rare and aggressive type of blood cancer. Non-Hodgkin’s lymphoma... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published... Continue Reading

Revlimid Approved for Mantle Cell Lymphoma (July 12, 2013)

The U.S. Food and Drug Administration (FDA) has approved Revlimid® (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies,... Continue Reading

Epigenetic Therapy Promising in Mantle Cell Lymphoma (July 10, 2013)

An epigenetic/immunotherapy regimen of cladribine, Rituxan® (rituximab), and vorinostat produced a 100 percent response rate and complete remissions in 86 percent of patients with newly diagnosed mantle... Continue Reading

R-CHOP Induction Plus Rituxan Maintenance Improves Remission in Older Patients with Mantle Cell Lymphoma (October 23, 2012)

Induction therapy with R-CHOP followed by maintenance with Rituxan® (rituximab) nearly doubled the remission duration in older patients with mantle cell lymphoma, according to the results of a study published... Continue Reading

Treanda More Effective than Standard R-CHOP for Non-Hodgkin’s Lymphoma (June 12, 2012)

The combination of Treanda® (bendamustine) and Rituxan® (rituximab) more than doubled progression-free survival compared with standard R-CHOP therapy among patients with indolent lymphoma and mantle... Continue Reading

Next Page »